RIGEL PHARMACEUTICALS INC (RIGL)
US7665597024 - Common Stock
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...
Rigel to Present at the Jefferies London Healthcare Conference
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...
Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update
Third quarter total revenue of $55.3 million, which includes TAVALISSE® net product sales of $26.3 million, REZLIDHIA® net product sales of $5.5 million and...
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2024 financial results after market close on...
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer,...
Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved...
Rigel to Present at the 2024 Cantor Global Healthcare Conference
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...
Rigel to Participate in Upcoming September Investor Conferences
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...
RIGL Stock Earnings: Rigel Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
RIGL stock results show that Rigel Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
RIGL Stock Earnings: Rigel Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rigel Pharmaceuticals (NASDAQ:RIGL) just reported results for the second quarte...
Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...
Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2024 financial results after market close on...
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved...
Noteworthy Tuesday Option Activity: ENVX, RIGL, LSTR
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced the completion of the transfer to Rigel of the New Drug Application (NDA)...
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
You don’t want to overlook these three penny stocks filled to the brim with the potential to make huge leaps in their respective markets.
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced one oral and four poster presentations at the European Hematology Association (EHA)...
Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the presentation of three posters at the 2024 American Society of Clinical Oncology...
Rigel to Present at the Jefferies Global Healthcare Conference
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and CEO, will present a company...
Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced upcoming presentations from their commercial and clinical-stage hematology and...
RIGL Stock Earnings: Rigel Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
RIGL stock results show that Rigel Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
RIGL Stock Earnings: Rigel Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rigel Pharmaceuticals (NASDAQ:RIGL) just reported results for the first quarter...
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2024, including sales of...
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2024 financial results after market close on...
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved...
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the...
Monday Sector Laggards: Biotechnology, Water Utilities
Commit To Buy Rigel Pharmaceuticals At $1, Earn 20.1% Annualized Using Options
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical...
RIGL Stock Earnings: Rigel Pharmaceuticals Beats Revenue for Q4 2023
RIGL stock results show that Rigel Pharmaceuticals beat on revenue for the fourth quarter of 2023.
RIGL Stock Earnings: Rigel Pharmaceuticals Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rigel Pharmaceuticals (NASDAQ:RIGL) just reported results for the fourth quarte...
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2023,...